Related Experiment Video
Updated: Dec 15, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Altered ANRIL Methylation in Epileptic Patients
Sara Mirzajani1, Soudeh Ghafouri-Fard1, Jafar Mehvari Habibabadi2
1Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Epilepsy patients show altered ANRIL long non-coding RNA expression. Hypomethylation of the ANRIL promoter in epilepsy patients may explain this dysregulation, offering insights into disease mechanisms.
Area of Science:
- Epigenetics
- Neuroscience
- Molecular Biology
Background:
- Long non-coding RNAs (lncRNAs) regulate cellular functions, including neuronal differentiation.
- Altered lncRNA expression is implicated in epilepsy pathophysiology.
- Antisense non-coding RNA in the INK4 locus (ANRIL) is significantly upregulated in epilepsy patients' peripheral blood.
Purpose of the Study:
- To investigate the methylation status of the ANRIL promoter in epilepsy.
- To explore the potential mechanism behind deregulated ANRIL expression in epilepsy.
Main Methods:
- High-resolution melting (HRM) analysis was used to assess ANRIL promoter methylation.
- The study included 40 patients with refractory epilepsy, 40 with non-refractory epilepsy, and 40 healthy controls.
Main Results:
- Hypomethylation of the ANRIL promoter was observed in both refractory and non-refractory epilepsy groups compared to controls.
- This hypomethylation correlates with the previously reported upregulation of ANRIL in epilepsy.
Conclusions:
- Altered methylation of the ANRIL promoter is a potential cause for its aberrant expression in the peripheral blood of epilepsy patients.
- Epigenetic modifications of lncRNAs like ANRIL may play a role in epilepsy pathogenesis.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

